Track BioLife Solutions, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioLife Solutions, Inc. BLFS · Stock Open BioLife Solutions, Inc. in new tab

38.61 USD
P/E
39.00
EPS
0.99
P/B
4.49
ROE
12.83
Beta
1.82
Loading chart...
Key Metrics
Earnings dateNov. 5, 2026
P/E39.00
EPS0.99
Book Value8.59
Price to Book4.49
Debt/Equity3.75
% Insiders2.606%
Growth
Revenue Growth0.22%
Earnings Growth-0.14%
Estimates
Forward P/E117.00
Forward EPS0.33

DCF valuation

Model fair value for BioLife Solutions, Inc. (BLFS)
Result
Sign in to run the valuation for BLFS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

BioLife Solutions, Inc. Logo BioLife Solutions, Inc. Analysis (BLFS)

United States Health Care Official Website Stock

Is BioLife Solutions, Inc. a good investment? BioLife Solutions, Inc. (BLFS) is currently trading at 38.61 USD.

In terms of valuation, the stock trades at a P/E ratio of 39.00. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: BioLife Solutions, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 0.33.

Investor FAQ

Does BioLife Solutions, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioLife Solutions, Inc.?

BioLife Solutions, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 0.99.

Company Profile

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Exchange Ticker
NCM (Australia) BLFS
FRA (Germany) BJX1.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 16, 2000 1:5
Jan. 29, 2014 1:14
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion